Posttraumatic Stress Disorder | Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder
Posttraumatic Stress Disorder research study
What is the primary objective of this study?
The objectives of the current study are 1. to evaluate the efficacy of escitalopram in treatment for post-traumatic stress disorder, 2. to find the structural changes of brain using magnetic resonance imaging and its association with the symptoms reduction, and 3. to look at the differences of brain imaging findings and symptoms changes according to genetic differences of brain-derived neurotrophic factor (a biological molecule facilitating neuronal growth in human).
Who is eligible to participate?
Inclusion Criteria: - 18-65 year-old male or female - PTSD diagnosed by SCID-IV Exclusion Criteria: - Previous or current treatment history for PTSD - Neurologic disease (eg., epilepsy, infarct, multiple sclerosis, brain tumor) - Any other axis I psychiatric disorder diagnosed by SCID-IV - Borderline personality disorder or antisocial personality disorder - IQ below 80 - Any contraindication to MRI scan - Any current psychotropic medication - Unstable medical illness or severe abnormality in laboratory test at screening assessment - Women who are pregnant, breastfeeding, or planning pregnancy - Any contraindications to drug used in the study (e.g., allergy, intolerance, etc.)
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Posttraumatic Stress Disorder
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:escitalopram (lexapro)0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: November 2008
Completed Date: February 2014
Phase: Phase 2
Primary Outcome: Changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach
Secondary Outcome: Change from baseline in Hamilton depression rating scale scores at 1st week
Study sponsors, principal investigator, and references
Principal Investigator: In Kyoon Lyoo, MD, PhD, MMS
Lead Sponsor: Seoul National University Hospital